These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25245581)

  • 1. Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases.
    Karlsson L; Zackrisson AL; Josefsson M; Carlsson B; Green H; Kugelberg FC
    Pharmacogenomics J; 2015 Apr; 15(2):165-71. PubMed ID: 25245581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood.
    Kingbäck M; Karlsson L; Zackrisson AL; Carlsson B; Josefsson M; Bengtsson F; Ahlner J; Kugelberg FC
    Forensic Sci Int; 2012 Jan; 214(1-3):124-34. PubMed ID: 21840145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically Based Pharmacokinetic Modeling to Unravel the Drug-gene Interactions of Venlafaxine: Based on Activity Score-dependent Metabolism by CYP2D6 and CYP2C19 Polymorphisms.
    Shen C; Yang H; Shao W; Zheng L; Zhang W; Xie H; Jiang X; Wang L
    Pharm Res; 2024 Apr; 41(4):731-749. PubMed ID: 38443631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A.
    Tozatto E; Benzi JRL; Rocha A; Coelho EB; Lanchote VL
    J Clin Pharmacol; 2021 Mar; 61(3):319-327. PubMed ID: 32974907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort.
    Kringen MK; Bråten LS; Haslemo T; Molden E
    J Clin Psychopharmacol; 2020; 40(2):137-144. PubMed ID: 32134850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible cardiac dysfunction after venlafaxine overdose and possible influence of genotype and metabolism.
    Castanares-Zapatero D; Gillard N; Capron A; Haufroid V; Hantson P
    Forensic Sci Int; 2016 Sep; 266():e48-e51. PubMed ID: 27328779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pitfalls and challenges associated with phenoconversion in forensic toxcicology.
    Drevin G; Picard N; Jousset N; Briet M; Abbara C
    Forensic Sci Int Genet; 2021 Mar; 51():102433. PubMed ID: 33278816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine.
    Kandasamy M; Srinivas P; Subramaniam K; Ravi S; John J; Shekar R; Srinivas N; Thangam S
    Eur J Clin Pharmacol; 2010 Sep; 66(9):879-87. PubMed ID: 20446083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of CYP2D6 Genotypes on Venlafaxine Metabolism in Japanese Psychiatric Patients With Depression.
    Komahashi-Sasaki H; Yasui-Furukori N; Sasaki T; Shinozaki M; Hayashi Y; Kato K; Inoue Y; Tsuchimine S; Watanabe T; Sugawara N; Shimoda K
    Ther Drug Monit; 2021 Oct; 43(5):681-687. PubMed ID: 33306568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?
    Taranu A; Colle R; Gressier F; El Asmar K; Becquemont L; Corruble E; Verstuyft C
    Pharmacogenomics; 2017 May; 18(7):639-650. PubMed ID: 28480819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine.
    Jornil J; Nielsen TS; Rosendal I; Ahlner J; Zackrisson AL; Boel LW; Brock B
    Forensic Sci Int; 2013 Mar; 226(1-3):e26-31. PubMed ID: 23332809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.
    Nichols AI; Lobello K; Guico-Pabia CJ; Paul J; Preskorn SH
    J Clin Psychopharmacol; 2009 Aug; 29(4):383-6. PubMed ID: 19593180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine.
    McAlpine DE; Biernacka JM; Mrazek DA; O'Kane DJ; Stevens SR; Langman LJ; Courson VL; Bhagia J; Moyer TP
    Ther Drug Monit; 2011 Feb; 33(1):14-20. PubMed ID: 21099743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting.
    Reis M; Lundmark J; Björk H; Bengtsson F
    Ther Drug Monit; 2002 Aug; 24(4):545-53. PubMed ID: 12142641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of CYP2D6 on venlafaxine metabolism in Trinidadian patients with major depressive disorder.
    Montané Jaime LK; Paul J; Lalla A; Legall G; Gaedigk A
    Pharmacogenomics; 2018 Feb; 19(3):197-212. PubMed ID: 29327975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2D6*10 polymorphism and the enantioselective O-desmethylation of S-(+)- and R-(-)-venlafaxine in Japanese psychiatric patients.
    Sasaki T; Yasui-Furukori N; Komahashi-Sasaki H; Shinozaki M; Hayashi Y; Kato K; Inoue Y; Tsuchimine S; Watanabe T; Sugawara N; Shimoda K
    Basic Clin Pharmacol Toxicol; 2021 May; 128(5):677-685. PubMed ID: 33470005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms.
    Vinetti M; Haufroid V; Capron A; Classen JF; Marchandise S; Hantson P
    Clin Toxicol (Phila); 2011 Nov; 49(9):865-9. PubMed ID: 22077251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.
    Shams ME; Arneth B; Hiemke C; Dragicevic A; Müller MJ; Kaiser R; Lackner K; Härtter S
    J Clin Pharm Ther; 2006 Oct; 31(5):493-502. PubMed ID: 16958828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population.
    Fukuda T; Nishida Y; Zhou Q; Yamamoto I; Kondo S; Azuma J
    Eur J Clin Pharmacol; 2000 May; 56(2):175-80. PubMed ID: 10877013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression.
    Men X; Taylor ZL; Marshe VS; Blumberger DM; Karp JF; Kennedy JL; Lenze EJ; Reynolds CF; Stefan C; Mulsant BH; Ramsey LB; Müller DJ
    Clin Pharmacol Ther; 2024 May; 115(5):1065-1074. PubMed ID: 38284409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.